BIOVECTRA signs service agreement with Acuitas Therapeutics for unique lipid nanoparticle (LNP) delivery system used in manufacturing mRNA-based therapies Post author: Post published: October 6, 2023 Post category:uncategorized BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service. You Might Also Like Exposure to endocrine-disrupting chemicals in early life linked to cravings for sugary and fatty foods July 13, 2025 Soy lysolecithin reduces salt-induced hypertension and cognitive decline July 31, 2026 New 3D structure reveals how cancer-linked BRD4 protein binds to chromosomes September 15, 2026
Exposure to endocrine-disrupting chemicals in early life linked to cravings for sugary and fatty foods July 13, 2025